drugset / Trial / NCT07687914
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past
Timeline
- Start
- 2026-07-23
- Primary completion
- 2027-07-23
- Completion
- 2028-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM27M | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 20 mg/kg | Intravenous |